If you have been reading about dose range and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-03-26. Numbers and descriptions here follow the published literature rather than marketing material.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
| Property | Value | Notes |
|---|---|---|
| Amino acid count | 15 residues | Synthetic pentadecapeptide chain |
| Sequence | GEPPPGKPADDAGLV | Single-letter amino acid code |
| Molecular formula | C62H98N16O22 | Free peptide, without counter-ion |
| Theoretical mass | Approximately 1419.5 daltons | Varies slightly with adducts and counter-ions |
| Origin | Fragment of a human gastric juice protein | Source of the BPC designation |
Purity is ordinarily reported as a percentage from reverse-phase high-performance liquid chromatography, where the area of the main peak is compared with the total peak area. Identity is confirmed by mass spectrometry, since the measured mass can be checked against the value calculated from the sequence. Some certificates also include amino acid analysis or sequence confirmation by tandem mass spectrometry. A single purity number does not describe the profile of related impurities, so the underlying chromatogram and spectrum usually carry more information than the headline figure.
Material of this kind is sold for laboratory research, and labels typically state that it is not intended for human or veterinary use. In many countries it is not an approved medicine, and sports antidoping rules place it among prohibited non-approved substances. Buyers commonly review a certificate of analysis, an independent test report, and the declared storage conditions. Batch-to-batch variation in purity and in counterion content is possible, and how much that variation affects experimental outcomes remains an open question.
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
BPC-157 is a synthetic peptide built from fifteen amino acid residues. Its sequence comes from a larger protein fragment that researchers isolated from human gastric juice and described as a body protection compound. The fragment contains glycine, glutamic acid, five prolines, lysine, alanine, two aspartic acids, leucine, and valine. The number 157 in the name refers to the position of the stretch within the parent protein. Material used in laboratories is manufactured rather than extracted from stomach fluid.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
Handling practice centers on limiting moisture, heat, and mechanical stress. Powder is typically allowed to reach room temperature before opening so that condensation does not form on the contents, and solutions are prepared with sterile or low-particulate water. Peptides can adsorb to certain plastics and membrane filters, so container and filter material is sometimes specified to reduce losses at low concentrations. Working aliquots are usually frozen separately rather than sampled repeatedly from one stock. Recording lot number, preparation date, and storage conditions supports later comparison between experiments.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated sequences and other synthesis by-products. Mass spectrometry, typically electrospray ionization coupled to liquid chromatography, confirms the expected mass and helps detect modifications. Amino acid analysis can verify composition when residue-level confirmation is needed. Because common impurities differ from the target by only one or two residues, chromatographic resolution often matters more than a single headline purity percentage. Impurity profiles are most informative when compared against a validated reference standard.
=== Breakdown of biopolymers === Biopolymers like cellulose, lignin, chitin, or starch may be broken down into their individual nanoscale building blocks, obtaining anisotropic fiber- or needle-like nanoparticles. The biopolymers are disintegrated mechanically in combination with chemical oxidation or enzymatic treatment to promote breakup, or hydrolysed using acid.
The Agong at the time, Ahmad Shah of Pahang, agreed with the proposals in principle, but baulked when he realised that the proposal would deem Sultans to assent to laws passed by state assemblies. Supported by the Sultans, the Agong refused to assent to the constitutional amendments, which had passed both houses of Parliament with comfortable majorities. When the public became aware of the impasse, and the Sultans refused to compromise with the government, Mahathir took to the streets to demonstrate public support for his position in mass rallies. The press took the side of the government. A large minority of Malays, including conservative UMNO politicians, and an even larger proportion of the Chinese community supported the Sultans. After five months, the crisis was resolved, as Mahathir and the Sultans agreed to a compromise. The Agong retained the power to declare a state of emergency. However, if he refused to assent to a bill, the bill would return to Parliament, which could then override Agong's veto. In 1984, Mahathir was re-elected unopposed as UMNO president for a second term.
==== Absorption ==== Pseudoephedrine is orally active and is readily absorbed from the gastrointestinal tract. Its oral bioavailability is approximately 100%. The drug reaches peak concentrations after 1 to 4 hours (mean 1.9 hours) in the case of the immediate-release formulation and after 2 to 6 hours in the case of the extended-release formulation. The onset of action of pseudoephedrine is 30 minutes.
Confucianism, Taoism, and Chinese Buddhism, as well as other various traditional Chinese philosophies, have influenced not only Han Chinese culture, but also the neighboring cultures in East Asia. Chinese spiritual culture has been long characterized by religious pluralism and Chinese folk religion has always maintained a profound influence within the confines of Chinese civilization both historically and in the modern era. Han culture has for long been influenced by Mahayana Buddhism, while in recent centuries Christianity has also gained a foothold among the population. Chinese folk religion is a set of worship traditions of the ethnic deities of the Han people. It involves the worship of various figures in Chinese mythology and history, personnel such as Guan Yu and Qu Yuan, and mythological creatures such as the Chinese dragon or family, clan and national ancestors. These practices vary from region to region and do not characterize an organized religion, though many traditional Chinese holidays such as the Duanwu (or Dragon Boat) Festival, Qingming Festival, Zhongyuan Festival and the Mid-Autumn Festival come from the most popular of these traditions. Taoism, another indigenous Han philosophy and religion, is also widely practiced by the Han in both its folk forms and as an organized religion with its traditions having been a source of vestigial perennial influence on Chinese art, poetry, philosophy, music, medicine, astronomy, Neidan and alchemy, dietary habits, Neijia and other martial arts and architecture.
After several months of work, Fermi's group had tentatively determined that lighter elements would disperse the energy of the captured neutron by emitting a proton or alpha particle and heavier elements would generally accomplish the same by emitting a gamma ray. This latter behavior would later result in the beta decay of a neutron into a proton, thus moving the resulting isotope one place up the periodic table. When Fermi's team bombarded uranium, they observed this behavior as well, which strongly suggested that the resulting isotope had an atomic number of 93. Fermi was initially reluctant to publicize such a claim, but after his team observed several unknown half-lives in the uranium bombardment products that did not match those of any known isotope, he published a paper entitled Possible Production of Elements of Atomic Number Higher than 92 in June 1934. For element 93, he proposed the name ausenium (atomic symbol Ao) after the Greek name Ausonia for Italy. Several theoretical objections to the claims of Fermi's paper were quickly raised; in particular, the exact process that took place when an atom captured a neutron was not well understood at the time. This and Fermi's accidental discovery three months later that nuclear reactions could be induced by slow neutrons cast further doubt in the minds of many scientists, notably Aristid von Grosse and Ida Noddack, that the experiment was creating element 93.
Sources: en.wikipedia.org
=== News === Erik Eckholm (May 6, 2008). "Reports Find Racial Gap in Drug Arrests". The New York Times. Webb, Gary. "War on drugs has unequal impact on black Americans." (Archive ) San Jose Mercury News. August 20, 1996.
=== Laboratory reactions === Sulfur dioxide is one of the few common acidic yet reducing gases. It turns moist litmus pink (being acidic), then white (due to its bleaching effect). It may be identified by bubbling it through a dichromate solution, turning the solution from orange to green (Cr3+ (aq)). It can also reduce ferric ions to ferrous. Sulfur dioxide can react with certain 1,3-dienes in a cheletropic reaction to form cyclic sulfones. This reaction is exploited on an industrial scale for the synthesis of sulfolane, which is an important solvent in the petrochemical industry.
=== Surgery === While the total mesorectal excision (TME) operation has become the surgical gold standard for the management of rectal cancer, this is not so for colon cancer. Recently, the surgical principles underpinning TME in rectal cancer have been extrapolated to colonic surgery. Total or complete mesocolic excision (CME), use planar surgery and extensive mesenterectomy (high tie) to minimise breach of the mesentery and maximise lymph nodes yield. Application of this T/CME reduces local five-year recurrence rates in colon cancer from 6.5% to 3.6%, while cancer-related five-year survival rates in patients resected for cure increased from 82.1% to 89.1%.
Myozyme costs an average of US$300,000 a year and must be taken for the patient's entire life, so some American health insurers have refused to pay for it. In August 2006, Health Canada approved Myozyme for the treatment of Pompe disease. In June 2007, the Canadian Common Drug Review issued its recommendations regarding public funding for Myozyme therapy. Their recommendation was to provide funding to treat a tiny subset of Pompe patients (Infants less one year of age with cardiomyopathy). In May 2010, the FDA approved Lumizyme for the treatment of late-onset Pompe disease. Lumizyme and Myozyme have the same generic ingredient (alglucosidase alfa) and manufacturer (Genzyme Corporation). The difference between these two products is in the manufacturing process. Myozyme is made using a 160-L bioreactor, while Lumizyme uses a 4000-L bioreactor. Because of the difference in the manufacturing process, the FDA claims that the two products are biologically different. Myozyme is FDA approved for replacement therapy for infantile-onset Pompe disease. In July 2021, the European Medicines Agency (EMA) recommended the authorization of avalglucosidase alfa. Avalglucosidase alfa (Nexviazyme) was approved for medical use in the United States in August 2021, and in the European Union in June 2022. In December 2022, the EMA recommended the authorization of cipaglucosidase alfa. The approval was given in June 2023. In the EU, the therapy is available to all age groups without restrictions on weight of patients.
Sources: en.wikipedia.org
The peptide is synthetic, but its sequence matches a segment of a protein present in human gastric juice. It does not occur as a free fifteen-residue peptide in the body.
Rodents account for the large majority of published experiments. Human data are sparse and mostly observational, so cross-species extrapolation remains uncertain.
It is not an approved therapeutic in most jurisdictions. Regulatory status varies by country, and several places restrict it as a research chemical.
Human data are limited. Most evidence comes from animal experiments and from small or uncontrolled reports. The absence of large trials means clinical effects and safety are not firmly established.